Literature DB >> 9437406

Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies.

L Skattum1, U Mårtensson, A G Sjöholm.   

Abstract

OBJECTIVES: The main purposes were to document manifestations associated with prolonged or clinically unexplained C3 deficiency and to approximate how often hypocomplementaemia of this kind is caused by C3 nephritic factors (C3 NeF), i.e. autoantibodies to alternative pathway C3 convertases. We also wished to distinguish between C3 NeF types I and II and to assess coincident autoantibody responses to the collagen-like region of C1q (C1qCLR).
SETTING: The investigation was based on serum samples referred to a specialized laboratory for complement analysis in the course of several years.
SUBJECTS: Twenty-five persons with C3 concentrations lower than 0.43 g L-1, a third of the normal, were included in the study.
RESULTS: Analysis using three methods provided evidence of C3 NeF in 20 persons with equal frequencies of C3 NeF types I and II. We also gave evidence of antibody specificity differences for the two types of C3 NeF. Six patients with C3 NeF type II showed antibodies to C1qCLR. Membranoproliferative glomerulonephritis was the predominant diagnosis and two patients had partial lipodystrophy reflecting the well-known association between these diseases and C3 NeF. Anaphylactoid purpura, systemic lupus erythematosus, and severe infection, mainly meningococcal disease, were also observed.
CONCLUSIONS: The study group was probably fairly representative of C3 deficiency syndromes as encountered in clinical practice. The findings emphasize the heterogeneity of C3 NeF, and that acquired C3 deficiency syndromes caused by C3 NeF should perhaps be considered more often in diagnostic work.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9437406     DOI: 10.1111/j.1365-2796.1997.tb00018.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  12 in total

Review 1.  Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-07-06

Review 2.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 3.  Applying complement therapeutics to rare diseases.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Despina Yancopoulou; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Clin Immunol       Date:  2015-09-01       Impact factor: 3.969

4.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  Recovery of renal function succeeding stem cell transplant: a case of C3 Glomerulonephiritis secondary to monoclonal gammopathy.

Authors:  Camilla Aakjær Andersen; Niels Marcussen; Jon Waarst Gregersen
Journal:  Clin Kidney J       Date:  2013-11-04

6.  Functional analyses of complement convertases using C3 and C5-depleted sera.

Authors:  Marcin Okroj; Emelie Holmquist; Ben C King; Anna M Blom
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

7.  Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.

Authors:  Danielle Paixão-Cavalcante; Margarita López-Trascasa; Lillemor Skattum; Patricia C Giclas; Timothy H Goodship; Santiago Rodríguez de Córdoba; Lennart Truedsson; B Paul Morgan; Claire L Harris
Journal:  Kidney Int       Date:  2012-08-01       Impact factor: 10.612

Review 8.  Complement diagnostics: concepts, indications, and practical guidelines.

Authors:  Bo Nilsson; Kristina Nilsson Ekdahl
Journal:  Clin Dev Immunol       Date:  2012-11-14

Review 9.  Meningococcal disease and the complement system.

Authors:  Lisa A Lewis; Sanjay Ram
Journal:  Virulence       Date:  2013-10-08       Impact factor: 5.882

10.  The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis.

Authors:  P Puri; G D Walters; M N Fadia; M Konia; K A Gibson; S H Jiang
Journal:  BMC Nephrol       Date:  2020-07-11       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.